An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

March 31, 2019

Conditions
Migraine Disorder
Interventions
BIOLOGICAL

ALD403 (Eptinezumab)

Trial Locations (20)

11229

Research Site, Brooklyn

14609

Research Site, Rochester

29464

Research Site, Mt. Pleasant

32720

Research Site, DeLand

33125

Massachusetts, Miami

33634

Research Site, Tampa

33880

Research Site, Winter Haven

34201

Research Site, Bradenton

37421

Research Site, Chattanooga

45432

Research Site, Dayton

55402

Research Site, Minneapolis

66206

Research Site, Prairie Village

76104

Research Site, Fort Worth

80918

Research Site, Colorado Springs

90404

Research Site, Santa Monica

92108

Research Site, San Diego

98007

Research Site, Bellevue

02131

Massachusetts, Boston

02760

Research Site, North Attleboro

02481

02481, Wellesley

Sponsors
All Listed Sponsors
lead

Alder Biopharmaceuticals, Inc.

INDUSTRY

NCT02985398 - An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine | Biotech Hunter | Biotech Hunter